In the late 90's there was a change in both the route of transmission and the people at risk for sporotrichosis. This zoonotic cat-man alternative transmission route elicited changes in strategies to control the epidemic. There was a progressive increase in the number of cases involving especially children and the elderly. In addition to becoming hyperendemic, uncommon clinical pictures like immunoreactive clinical presentations or severe systemic cases have emerged. New species were identified and classified through molecular tools using more virulent clinical isolates, like S. brasiliensis, compared to the environmental isolates. Likewise, different species of Sporothrix have been associated with different geographic regions. The serological and molecular techniques are used as an auxiliary tool for the diagnosis and/or for species identification, although the isolation and the identification of Sporothrix spp. in clinical specimen is still the gold standard. Currently sporotrichosis epidemics requires the knowledge of the epidemiological-molecular profile to control the disease and the specific treatment. Itraconazole, potassium iodide, terfinafine, and amphotericin B are the available drugs in Brazil to treat sporotrichosis. The drug of choice, its posology, and treatment duration vary according to the clinical presentation, the Sporothrix species, and host immune status. New treatment choices, including a vaccine, are being developed; nevertheless, more clinical trials are required to confirm its efficacy.
INTRODUCTION
Sporotrichosis is a subacute or chronic infection, caused by thermodimorphic fungi of the genus Sporothrix. It is a cosmopolitan disease, occurring preferably in tropical and subtropical regions, and is considered the most frequent subcutaneous mycosis in Latin America, where it is endemic. 1 Sporotrichosis was first described in 1898, by the medical student Benjamin Schenck, at the Johns Hopkins Hospital, in Baltimore, USA. 2 The fungus isolated from skin lesions on the right upper limb of a patient treated by Schenck was evaluated by the pathologist Erwin F. Smith, and identified as a species belonging to the genus Sporotrichum. In 1900, Hektoen and Perkins reported another case in Chicago and proposed a new name, Sporothrix schenckii, although Sporotrichum schenckii was used for decades. 3 Due to the reproduction characteristics of this genus, the binomial was changed to Sporothrix schenckii. 4 Currently, the species involved in the human or animal disease, and other that are environmental, have been recognized. 5 In the early 20th century, in France, sporotrichosis was a common disease, as were the reports of the extracutaneous clinical forms. 3 In Brazil, Lutz and Splendore firstly described infections in rats and humans, demonstrating the presence of asteroid bodies in tissues, which are useful for the histopathological diagnosis of this mycosis. 6 
EPIDEMIOLOGY AND ETIOPATHOGENESIS
For a long time, sporotrichosis was known as the "rosebush mycosis", or the "gardener's mycosis", given that the infection usually resulted from the agent's inoculation on the skin or mucous membrane, by trauma with contaminated plant material. However, some cases of zoonotic transmission have been reported, as well as less frequent cases of inhaled infective fungal propagules, clinically presenting as a systemic mycosis. 7, 8 Occasionally, there may be an environmental transmission of sporotrichosis, classically associated with soil manipulation activities, whether for occupational or leisure reasons; in outbreaks such as those that occurred in the USA, especially in the Mississippi Valley, in the 80's, involving reforestation workers infected by pine trees and moss seedlings; also as microepidemics like that which occured in the early 90's, with people infected by the contact with hay stored in an abandoned house where Halloween parties were held; as well as large epidemics, such as that which occurred in the 40's, when three thousand miners in South Africa were infected by the contact with contaminated wood supporting beams, being considered the largest epidemic in the 20th century. [9] [10] [11] More recently, 457 cases were described between 2007 and 2009 in a province in the northeast China, where the disease is endemic. 12 The zoonotic transmission of sporotrichosis was described sporadically involving accidents with snakes and birds, also mosquito, rat, horse, squirrel, and fish bites. 3, 13, 14 Epidemics were reported in Uruguay and, more recently, in Brazil and Argentina, related to armadillo hunting, given the close relation of the armadillo with the soil. 15, 16 The importance of the cat in zoonotic transmission was first noticed when an outbreak involving five people exposed to a sick animal was reported. 17 In Brazil, the main zoonotic sporotrichosis outbreaks, involving humans and a small group of domestic cats, occurred in the states of São Paulo and Rio Grande do Sul, with an effective epidemiological control. 18, 19 In September 1997, the first cases of the greatest feline zoonotic transmission epidemic ever described were admitted at the Pedro Ernesto University Hospital, Rio de Janeiro. Three people from the same family were infected by a sick cat that died (authors' report, unpublished) ( Figure 1 ). Then, the first publications about this epidemic, which is currently considered to be hyperendemic in the state of Rio de Janeiro, appeared. 20, 21 The capital city and the surrounding municipalities known as "Baixada Fluminense" are currently the most affected places where poor socioeconomic conditions are observed. The epidemiological profile is mainly characterized by children, elderly, and women, because these groups usually have direct and more frequent contact with these animals. 22 Along with the consolidation of the urban epidemics, vulnerable patients also became a worrisome at-risk population, especially those infected by the human immunodeficiency virus. 23 Since 2013, the notification is mandatory in the state of Rio de Janeiro, but not in the other Brazilian states. Therefore, prevalence and incidence measures are obtained mainly based on cases reported in the literature, certainly underestimating the real epidemiological importance, especially regarding outbreaks and epidemics.
Although human or animal sporotrichosis cases were published in the states of Amazonas, Pará, Minas Gerais, Espírito Santo, São Paulo, Rio de Janeiro, Paraná, and Rio Grande do Sul, most cases occur in the South and Southeast Brazil. 24 The advances in the microbiological knowledge along with the use of molecular tools led to important advances concerning epidemiological studies, enabling the identification of the Sporothrix species in 14 Brazilian states, indicating that sporotrichosis is more widespread than previously thought for the Brazilian territory. Even though sporotrichosis has been described worldwidely, there is a curious divergence regarding the geographic distribution and the incidence of the etiological agents. 25 Indeed, some spe- Melanin induces fungal escape from the host's defenses, and is also considered a resistance factor against some antifungal drugs, such as amphotericin B, itraconazole and terbinafine. 45, 46 The virulence profiles change depending on the pathogen characteristics and the host defenses. Sporothrix brasiliensis is the most virulent species, due to its ability to invade tissue and lead to death, whereas S. schenckii has different levels of virulence and S. globosa exhibits little or no virulence in murine models. 42, [47] [48] [49] The environmental species of Sporothrix present low virulence in murine models, with low invasive potential, and the host is able to control the infection a few weeks after inoculation.
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The host's defense against the Sporothrix species
has not yet been established. The fungus' cell wall components, especially the 70kDa glycoprotein (gp70), has a protective effect in the host, mediated by T-helper cells (Th1 in humans), but paradoxically, it also makes the adherence of conidia to the epithelium, increasing fungal invasive potential. The cell-mediated immune response seems to be responsible for eliminating or controlling infection. However, the humoral immune response elicits specific antibodies against the Sporothrix' cell wall. 5, 50 The dissemination of sporotrichosis is usually related to cellular immunity deficiencies, such as AIDS.
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CLINICAL ASPECTS
Usually, the clinical manifestations of sporotrichosis are divided into cutaneous and extracutaneous, the former is more frequent. 22 After the zoonotic sporotrichosis epidemic in the state of Rio de Janeiro, new clinical presentations, uncommon until then, were identified. For this reason, a new classification was proposed, to better describe the clinical features of the patients cared by the reference sporotrichosis teams. 52 In the present article, the authors propose an update of this clinical classification based on the group's expertise ( Table 1) .
Nearly 80% of the affected patients present the lymphocutaneous form. 52 Initially, the lesion has a papulonodular appearance where the fungus was introduced into the skin, appearing between two to four weeks after the trauma. Afterwards, the lesion may ulcerate, and fistulize draining a purulent discharge. This is so-called the inoculation chancre. The lesions, usually nodules, progress along the regional lymphangitic channels, upwards or downwards depending on the anatomical site, after some weeks. Later, these nodules, may ulcerate, fistulize, and heal, caractherizing a gumma In general, these patients are immunocompetent individuals who describe having multiple traumas.
Although any mucous membrane may be affected by sporotrichosis, the ocular mucosa is more commonly involved, causing conjunctivitis, episcleritis, uveitis, choroiditis, and retrobulbar lesions, among others ( Figure 4A ). [53] [54] [55] When the lacrimal duct is affected, dacryocystitis may occur as sequela. 56, 57 The retrobulbar lesions, such as chorioretinitis, are more frequently related to hematogenous spread, and anterior lesions are associated with the fungal innoculation. The simultaneous affection of the ocular mucosa and the regional lymph nodes is not rare, and it is one of the causes of the Parinaud syndrome. 58 The bones and joints may be involved by direct trauma, by the invasion through a preexisting overlying cutaneous lesion or secondary to a hematogenous spreading, the latter at highest risk of [61] [62] [63] [64] Probably the disease is misdiagnosed in areas with high endemicity, either due to the lack of knowledge by the medical doctors, or to the unspecific clinical signs and symptoms. 65 The imunosuppressed patients are at higher risk for bloodstream dissemination of sporotricosis due to alcoholism, or the chronic use of illicit drugs, the use of immunosuppressive medication, or secondary to immunodeficiency such as AIDS. In theses cases the bones and joints, the lungs and central nervous system, in addition to the skin and mucous membranes, are preferably affected, although any organ may be involved ( Figures 3D-F At the other end, as occurs in other infectious diseases, some patients heal spontaneously, while others develop hypersensitivity clinical forms, such as erythema nodosum, erythema multiforme, and Sweet's syndrome due to an exacerbated immune response against the fungus. Also, reactive arthritis can occur, it is usually polyarticular and migratory, frequently disappearing with the specific treatment for sporotrichosis ( Figures 4B-C) . [67] [68] [69] In general, the lesions heal leaving fibrotic scars that may alter the organ function depending on the site of infection, for instance, the tear duct or the lungs. Unaesthetic scars are particularly important in younger patients, especially in exposed areas, given that the disease leads to fibrosis, sometimes causing tissue or hair loss, such as eyelashes, in the case of bulbar conjunctival lesion. 52 The children, the elderly, the pregnant women, and the immunosuppressed AIDS patients are groups that require a special attention. 70, 71 Children generally have more prolonged and frequent contact with animals and, therefore, are commonly infected. Nevertheless, they also exhibit a greater immunological resistance with limited lesions such as the fixed form, usually on the face; exhibiting slightly elevated serological titers. 71 The facial contact with animals also predisposes this age group to ocular mucosal lesions. On the other hand, the task of taking care of animals is usually assigned to the elderly, especially females. In this age group, the host immune defense is declining, which means that, in many times, there may be a more extensive and severe clinical presentation of the disease.
DIFFERENTIAL DIAGNOSIS
Due to the diversity of clinical presentations, sporotrichosis may be clinically similar to many other infectious and non-infectious diseases, both tegumentary and systemic. The most common are tegumentary leishmaniasis, pyodermitis, cat-scratch disease, cutaneous nocardiosis, chromomycosis, syphilis, rosacea, granuloma annulare, pyoderma gangrenosum, osteomyelitis, arthritis with a different etiology, such as rheumatoid, also cutaneous and pulmonary tuberculosis, tumoral lesions, especially in the lungs and in the central nervous system, and meningitis, besides others. In regions of high endemicity, the epidemiological background must be taken into consideration.
LABORATORY DIAGNOSIS Mycology
The gold standard for the diagnosis of sporotrichosis is the isolation and the identification of the Sporothrix species from clinical samples such as skin lesions, biopsy, aspirated from floating abscesses, as well as sputum, pus, synovial fluid, blood, and cerebrospinal fluid. 8, 72 It is a simple and low-cost diagnostic method, although it may not be useful for some systemic and atypical forms of sporotrichosis. 52, 73 Seldom, the direct microscopy (DM) made with potassium Colonies are identified phenotypically by the membranous appearance of the surface, off-white to cream color and a black halo, or they may be dark from the beginning, depending on the species, and on the nutritional and environmental conditions (Figure 5A) . The colony microscopy of the clinical clade exhibit delicate branched septate hyaline hyphae, a conidiophore producing at the tip pyriform, oval to round, hyaline conidia, arranged sympodially as a bouquet, in addition to sessile pigmented conidia ( Figure  5B ). 33, 74 The thermodimorphism of the Sporothrix species of clinical Assimilation of sugars such as glucose, raffinose, ribitol, and sucrose are some of the carbon compounds used in physiological tests; the Sporothrix isolates show different pattern of assimilation.
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Histopathology
The sensitivity of histopathology test in humans is low due to the paucity of fungal elements in the tissue. The inflammatory infiltrate is better observed by hematoxilyn-eosin stain, and PAS or methenamine silver is used to identify the fungal structures. The produced mAb P6E7 antibody against the gp70 caused in vivo protection through passive immunization of mice infected with S.
schenckii. It is considered to be a strong candidate for a therapeutic vaccine against sporotrichosis.
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These tests are not commercially available, being restricted to certain research centers, especially due to the lack of Public
Health financing in Brazil, where sporotrichosis is endemic or hyperendemic, depending on the country region.
Molecular
The phenotypical identification of the different Sporothrix species have, as a disadvantage, the use of tools that are usually laborious, longstanding, with variable results, especially for the species inserted in the clinical clade, which could lead to incorrect identification. 39, [95] [96] [97] Nowadays, the molecular boundaries among the Sporothrix spp. are defined, enabling the development of numerous genetic markers for recognition and identification of clinical specimens. 44 The development of fast and low-cost genotyping methods is important for diagnosis, as well as for epidemiological studies, considering that the pathogenic species in Sporothrix differ in terms of their geographical range, virulence, and susceptibility to antifungal drugs. of Sporothrix. 31 The human and animal origin specimens are distributed in the S. brasiliensis, S. schenckii, S. globosa, and S. luriei clades.
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The environmental Sporothrix species are located at a relatively large phylogenetic distance. However, it is worth noticing that, in the environmental clade, in addition to the ITS region, the use of protein coding genes for the recognition of cryptic species, especially in the S. pallida complex, will be required. 38 Protein coding genes, such as Itraconazole is considered the drug of choice due to its effectiveness, safety, and posologic convenience, and it is classified having an AII scientific evidence level. 72, 106 It is a fungistatic drug that acts by inhibiting the synthesis of ergosterol in the fungus cell wall.
It may be used in healthy patients with limited lesions, as well as in immunosuppressed patients and in the systemic form, but not in life-threatening cases of dissemination/sepsis. It is offered in 100mg capsules and must be administered along with the main meals, for better absorption. The dose ranges from 100 to 400mg/day, depending on the disease severity. The treatment should be started with 100mg/day, which is effective in most cases. It may be administered continuously or intermittently (pulse). 107 The main adverse effects reported are headache and gastrointestinal disorders, which are, in most cases, tolerable. It is hepatotoxic, teratogenic, and embryotoxic, and may not be used in patients with liver diseases or in pregnant women (risk category C). Its greatest disadvantage is the possibility of drug interaction, as a consequence of the dependent metabolism on CYP 3A4 common to other several drugs. It may cause an increase or a reduction of serum drug concentrations frequently used by elderly patients usually affected, also these drugs may reduce or increase serum itraconazole levels. Childbearing women must be warned about the risk of oral contraceptive effect reduction. In addition, there is a risk of sudden death, especially in patients suffering from congestive heart failure, due to its negative inotropic effect on the cardiac muscle. 108 Complete blood count, biochemistry, and liver function tests should be performed prior to the treatment and after 3-4 weeks. If serum levels are whithin normal ranges, the tests should only be repeated at the end of the treatment.
Potassium iodide (KI) has been used for treating sporotrichosis, since 1903, as initially suggested by Saboraud. 7 At that time, specific antifungal drugs were not available and iodide was used for several infectious and non-infectious diseases. The KI mechanism of action is not yet completely understood, despite its already known action on the immune response, destructuring granulomas, on neutrophil chemotaxis, as well as on phagocytosis of Sporothrix cells. 109, 110 The scientific evidence level is AII, the same of itraconazole, and it may be prepared as saturated or concentrated solution. In the saturated solution, each drop contains 0.07g, and in the concentrated solution, 0.05g. 111 Doses of up to 4-6g/day for adults are recommended. However, a recent study has demonstrated that doses of 1-2g/day for children, and 2-4g/day for adults, administered t.i.d with milk, juice or yogurt are effective to cure most patients. 112 The treatment starts with lower doses, increasing daily in both intakes until the effective and tolerated dose is reached. This is especially useful for the elderly and for children, as it is available in the liquid form. KI is indicated for localized sporotrichosis cases in patients whose immunity is preserved, but it may also be used in immunoreactive forms, such as erythema nodosum or reactive arthritis, due to its immunomodulatory effect. It is contraindicated for patients with thyroid dysfunction, kidney failure, iodine allergy, autoimmune diseases, and in pregnant and nursing women (risk category D). Up to now, it is not indicated for patients who have deficiency of immune response, and extensive or systemic clinical manifestations. The main adverse events are metallic taste and nausea, followed by acneiform eruption. In addition to the laboratory tests for monitoring itraconazole use, for KI it is important to check the TSH and T4 serum levels during treatment, although a slight increase in TSH serum levels is considered to be physiological. This is the only drug recommended for pregnant women with severe disease, given that it is not teratogenic, although it may worsen metabolic disorders that are already common during pregnancy. 115 Sporotrichosis treatment must be maintained until the clinical cure is reached, which usually occurs within 2 to 3 months. It is not necessary to maintain the drug use for 1 to 3 months after the cure, as previously recommended. Clinical cure is considered when there is no disease's activity, such as pus, exsudation, or crust in the skin lesions, even if a discrete erythema, fibrosis, or milia appear during the healing process. Systemic forms require longer treatment, ranging from 6 to 12 months.
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Miscellaneous
The local heat was initially used to treat chromomycosis, it is based on the fungus' thermosensitivity, and may be useful when conventional drugs are contraindicated. 115, 116 Cryosurgery using liquid nitrogen may be used as a therapeutic complement in refractory cases, especially when lesions are crusty and infiltrate, as well as in isolated cases of localized lesions in immunocompetent patients.
Electrosurgery and surgical removal of small lesions constitute other therapeutic options in selected cases. All therapeutic methods described may be used as monotherapy or as adjuvant treatment.
Photodynamic therapy was tested in vivo and in vitro for the treatment of skin sporotrichosis. 
Other considerations
There are important differences regarding in vitro sensitivity to the main antifungal drugs and the different etiological agents, reinforcing the importance of the correct identification for properly treating sporotrichosis. Sporothrix brasiliensis presents the best response to antifungal drugs, while S. mexicana is more tolerant to drug action. 118 Epidemiological analyses reveal that the in vitro susceptibility profile has been changing over time, emphasizing the emergence of S. brasiliensis isolates tolerant to itraconazole. 119 In this context, potassium iodide, terbinafine, and posaconazole may be alternative drugs against S. brasiliensis, especially in refractory cases, or for those with no satisfactory in vivo response to itraconazole.
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FIgure 7: Algorithm for the treatment of sporotrichosis. LC -lymphocutaneous; CF -fixed cutaneous; KI -potassium iodide; ITZitraconazole; TBF -terbinafine; AmB -amphotericin B
Modified from: Orofino-Costa, et al. 2015 70 KI has been used in association with itraconazole, for refractory mycosis in felines. However, its use in immunosuppressed humans needs to be better evaluated due to the possibility of changes in the immunological reactivity, and worsening of the underlying disease. 120 This association has been used in humans with conidiobolomycosis. 121 The effectiveness of this combination of drugs is prob- 
PERSPECTIVES
For over a century, sporotrichosis was described as an occupational disease, with a strong rural profile. However, in the last decades Sporothrix spp. as a threat to the warm-blooded vertebrate hosts' health has emerged. The close relation between S. brasiliensis and the feline host is curious, so that it causes large epizooties in urban areas. 124 Indeed, zoonotic pathogens are more often associated with emerging diseases than the non-zoonotic pathogens. and the humoral activity reconducted the seek for specific antigens that could be used in the diagnosis and antibodies based vaccines. 5 Anti-gp70 antibodies are potentially useful for disease's therapy because they strongly reduce the host fungal burden, thus preventing Sporothrix adhesion to the extracellular matrix components, or inducing the yeasts opsonization in the host-pathogen interaction. 126 The need to develop new antifungal drugs is encouraged by the increasing number of refractory cases resulting from the emergence of the resistance phenotype among the etiological agents. 127 Currently, researches on alternative treatments for sporotrichosis reveal promising molecules, such as terpinen-4-ol and farnesol, miltefosine, TCAN26 (a structural analogous of miltefosine) and the H3 molecule (an inhibitor of the sterol methyltransferase enzyme). [127] [128] [129] [130] [131] However, it should be pointed out that it is still necessary to use appropriate animal models and clinical tests to ensure the effective- 
